PainReform licenses Encore's post-surgical pain product
This article was originally published in Scrip
The pain management company PainReformhas entered into its first major licence agreement by signing a deal withEncore Therapeutics, which gives the Israeli firm exclusive North American rights to Encore's post-surgical pain product, ETI-211, as well as the option to expand the agreement to other countries including Japan and the EU.
You may also be interested in...
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.